Day: August 20, 2020

BOCA RATON, Fla., Aug. 20, 2020 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT) (the “Company” or “ADT”), a leading provider of security, automation, and smart home solutions serving consumer and business customers in the United States, announced today that Prime Security Services Borrower, LLC, a Delaware limited liability company (the “Issuer”), and Prime Finance Inc., a Delaware corporation (the “Co-Issuer” and, together with the Issuer, the “Issuers”), its indirect wholly owned subsidiaries, have completed their previously announced offering (the “Offering”) of $1,000 million aggregate principal amount of 3.375% first-priority senior secured notes due 2027 (the “Notes”). The Notes are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).The gross proceeds from the Offering were $1,000...

MILTON, N.Y., Aug. 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Sono-Tek Corporation (OTCQX: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that it held its Annual Shareholders Meeting on August 20, 2020 as a virtual meeting, due to the coronavirus. The presenters safely gathered at the Company’s headquarters in Milton, New York, and the presentation is available online at the Company’s website, http://www.sono-tek.com/investor-relations/. The results of Fiscal Year 2020, which ended on February 29, 2020, were discussed.During the meeting, Dr. Christopher L. Coccio, Chairman and CEO, highlighted the 2020 fiscal year business performance which resulted in a more than 32% year-over-year increase in sales to $15.3 million, and a seven fold increase in net income to over $1.1 million.  ...

FREEHOLD, NJ, Aug. 20, 2020 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE: UMH) today announced that it has successfully completed the financing of 28 of its unencumbered communities, containing approximately 4,100 sites, through Wells Fargo Bank, N. A. for total proceeds of approximately $106 million. This Federal National Mortgage Association (Fannie Mae) credit facility has a 10-year maturity with a 30-year amortization schedule. Interest is at a fixed rate of 2.62%. The proceeds will be used to redeem our 8% Series B Perpetual Preferred Stock and to also invest in additional acquisitions, expansions and rental homes further enhancing our ability to provide quality affordable housing in the markets that we serve.Samuel A. Landy, President and Chief Executive Officer commented, “We are very pleased to continue our strong...

CHICAGO, Aug. 20, 2020 (GLOBE NEWSWIRE) — SP Plus Corporation (SP+), (Nasdaq: SP), North America’s leading provider of parking, transportation and mobility-related services, today announced the selection of ChargePoint as its preferred provider for expanding its electric vehicle (EV) charging program.SP+ selected ChargePoint, the world’s largest manufacturer of EV charging stations with a full range of smart solutions, to accelerate its plan to offer drivers the convenience of charging their vehicles while parking at an SP+ facility while they work, shop, play or stay home.“We chose ChargePoint because they match our commitment to accommodating the future demand for e-mobility which supports the reduction of greenhouse gas emissions. They are also networked to help us remotely manage the charging stations and calculate our progress,”...

ATLANTA, Aug. 20, 2020 (GLOBE NEWSWIRE) — Atlantic Capital Bancshares, Inc. (NASDAQ: ACBI)  (“Atlantic Capital”) announced today the completion of a private placement of $75 million of 5.5% fixed to floating rate  subordinated notes due 2030 (the “Notes”) to certain qualified institutional buyers and accredited investors.The Notes are unsecured and have a ten-year term, maturing September 1, 2030, and will bear interest at a fixed annual rate of 5.5%, payable semi-annually in arrears, for the first five years of the term. Thereafter, the interest rate will reset quarterly to an interest rate per annum equal to a benchmark rate (which is expected to be Three-Month Term SOFR) plus 536.3 basis points, payable quarterly in arrears.The Notes have been structured to qualify as Tier 2 capital for Atlantic Capital for regulatory capital...

TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) — ECN Capital Corp. (“ECN Capital” or the “Company”) today announced that it has filed a notice of intention with the Toronto Stock Exchange (the “TSX”) to renew its normal course issuer bid (the “Common Share Bid”) for its common shares. The Company also announced that it has filed a notice of intention with the TSX to commence a normal course issuer bid (the “Preferred Share Bid” and, together with the Common Share Bid, the “Bids”) for its Series A 6.50% Rate Reset Preferred Shares and Series C 6.25% Rate Reset Preferred Shares (collectively, the “Preferred Shares”).If these notices are accepted by the TSX, the Bids would permit the Company to repurchase for cancellation, at its discretion during the 12 months following such acceptance, up to 10% of the “public float” (calculated in accordance...

Company AnnouncementNovartis intends to transition availability of Arzerra® (ofatumumab) to an oncology access program for chronic lymphocytic leukemia patients in the U.S.Genmab receives USD 30 million from Novartis as payment for lost potential royalties and improves 2020 financial guidance             Copenhagen, Denmark; August 20, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that Novartis intends to transition availability of Arzerra® (ofatumumab) to an oncology patient access program that will provide Arzerra at no cost to chronic lymphocytic leukemia (CLL) patients in the U.S. This program will be facilitated through the Patient Access Novartis Oncology (PANO). As a consequence, Novartis will pay Genmab a lump sum of USD 30 million as payment for lost potential royalties. Arzerra was developed by Novartis under a license agreement...

BOULDER, Colo., Aug. 20, 2020 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that the company held a Type C meeting with the FDA Office of  Oncologic Diseases on August 11, 2020 to discuss miRagen’s future clinical development plans for cobomarsen for the potential treatment of Adult T-Cell Leukemia/Lymphoma (ATLL).“We received clear guidance from the FDA on a potential path to registration in this ultra rare indication based upon a small randomized controlled trial with a primary endpoint of progression free survival that is appropriate for a maintenance therapy. With additional cobomarsen data from the ongoing Phase 2 SOLAR trial in Cutaneous...

ATLANTA, Aug. 20, 2020 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE: OXM) will report its fiscal second quarter ended August 1, 2020 financial results on Thursday, September 3, 2020 after the market close. The Company will also hold a conference call with senior management to discuss its financial results at 4:30 p.m. ET.A live webcast of the conference call will be available on the Company’s website at www.oxfordinc.com. Please visit the website at least 15 minutes early to register and download any necessary software.A replay of the webcast will be available on the Company’s website at www.oxfordinc.com through September 17, 2020 by dialing (412) 317-6671 access code 13708106.About OxfordOxford Industries, Inc., a leader in the apparel industry, owns and markets the distinctive Tommy Bahama®, Lilly Pulitzer® and Southern Tide®...

Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021Completed construction of cGMP clinical manufacturing facilityCompleted initial public offering of common stock on July 14, 2020, raising $289.8 million in gross proceedsCash and cash equivalents of $341.8 million (pro forma) as of June 30, 2020, believed to be sufficient to fund operations into at least the second half of 2023SOUTH SAN FRANCISCO, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the second quarter ended June 30, 2020, and highlighted recent corporate accomplishments.“Nkarta made outstanding progress in the second quarter...